

NORTHWEST AIDS EDUCATION AND TRAINING CENTER

NNRTI Resistance

Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington

Presentation prepared by: Brian R. Wood, MD Last Updated: 5/16/13



NNRTI Resistance

- Efavirenz
- Nevirapine
- Rilpivirine
- Etravirine




Stanford Database

STANFORD UNIVERSITY HIV DRUG RESISTANCE DATABASE

A curated public database designed to represent, store, and analyze the divergent forms of data underlying HIV drug resistance.

HOME GENOTYPE-RX GENOTYPE-PHENO GENOTYPE-CLINICAL HIVdb PROGRAM



http://hivdb.stanford.edu



Stanford Database

Reverse Transcriptase	Protease	Integrase
Enter Mutation List: k103n	Enter Mutation List:	Enter Mutation List:
OR	OR	OR
Use The Pulldown Menus: 41 44 62 65 \div \div \div 67 69 70 74 \div \div \div 75 77 90 98 \div \div \div 100 101 103 106 \div \div N \div \div 108 115 116 118 \div \div 106 107 107 107 108 106	Use The Pulldown Menus: 10 11 13 16 $ +$ $ +$ $ +$ $ +$ 20 23 24 30 $ +$ $ +$ $ +$ $ +$ 32 33 35 36 $ +$ $ +$ $ +$ $ +$ 43 46 47 48 $ +$ $ +$ $ +$ $ +$ 50 53 54 58 $ +$ $ +$ $ +$ $ +$	Use The Pulldown Menus: 51 54 66 68 $ +$ $ +$ $ +$ $ +$ 74 92 95 97 $ +$ $ +$ $ +$ $ +$ 114 121 125 128 $ +$ $ +$ $ +$ $ +$ 138 140 143 145 $ +$ $ +$ $ +$ $ +$ 146 147 148 151 $ +$ $ +$ $ +$ $ +$
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	153 154 155 157 + + + + 163 203 230 263 + + + +

ech●

Stanford Database

Drug Resistance Interpretation: RT

NRTI Resistance Mutations: NNRTI Resistance Mutations: Other Mutations:		None K103N None		
Nucleoside RTI			No	n-Nucleoside RTI
lamivudine (3TC)	Susceptible		efavirenz (EFV)	High-level resistance
abacavir (ABC)	Susceptible		etravirine (ETR)	Susceptible
zidovudine (AZT)	Susceptible		nevirapine (NVP)	High-level resistance
stavudine (D4T)	Susceptible		rilpivirine (RPV)	Susceptible
didanosine (DDI)	Susceptible			
emtricitabine (FTC)	Susceptible			
tenofovir (TDF)	Susceptible			

RT Comments

NNRTI

• K103N causes high-level resistance to NVP, and EFV. it has no effect on ETR or RPV susceptibility.

Mutation Scoring

RT	3TC	ABC	AZT	D4T	DDI	FTC	TDF	EFV	ETR	NVP	RPV
K103N	-	-	-	-	-	-	-	<u>60</u>	0	<u>60</u>	<u>0</u>
Total:	0	0	0	0	0	0	0	60	0	60	0

- A 32-year-old man presents after several missed visits. He reports imperfect adherence to tenofovir-emtricitabineefavirenz (*Atripla*). HIV RNA level (viral load) has increased from undetectable to 3,410 copies/mL.
- Genotype resistance assay shows: K103N
- Are other NNRTI's an option for this patient?



Efavirenz Resistance

- Most common mutation: K103N
- May be followed by: G190A/S, Y188L/H/C, K101E, L100I, accessory mutations
- *Efavirenz has long half-life and low barrier to resistance, so K103N often the first mutation with Atripla failure





	Efavirenz	Nevirapine	Rilpivirine	Etravirine
K103N	60	60	0	0

*Key points:

- K103N knocks out efavirenz and nevirapine
- Rilpivirine remains active *in vitro*; clinical data limited
- Etravirine still works unless additional mutations present

Penalty score ≥60: high-level resistance 30-60: intermediate-level resistance 10-30: low-level resistance Less than 0: hypersusceptible



- A 55-year-old man has had poor adherence to tenofoviremtricitabine (*Truvada*) and nevirapine (*Viramune*). HIV RNA level has risen to 1,250 copies/mL.
- What is the most likely nevirapine-associated resistance mutation?



Nevirapine Resistance

- Most common: **Y181C**
- Also possible: Y181I/V, G190A/S/E/Q, Y188L/H/C, K103N/ S/T, K101E, A98G, accessory mutations

Libre JM, Schapiro JM, Clotet B. CID. 2010;(50),872-881.





	Efavirenz	Nevirapine	Rilpivirine	Etravirine
Y181C	30	60	30	30

*Key point: the most common nevirapine mutation affects all NNRTI's, including etravirine

Penalty score >60: high-level resistance 30-60: intermediate-level resistance 10-30: low-level resistance Less than 0: hypersusceptible



- A 35-year-old woman has imperfect adherence to tenofoviremtricitabine-rilpivirine (*Complera*). HIV RNA level is 4,950 copies/mL.
- What is the most likely rilpivirine-associated resistance mutation?



Rilpivirine Resistance

- Most common rilpivirine mutation: E138K
- With Complera failure, most often see: E138K + M184I
 - M184I enhances rilpivirine resistance and causes emtricitabine resistance at the cost of viral fitness
- Other mutations: V90I, K101E/P/T, V179I/D/L, Y181C/I/V, V189I, H221Y, F227C/L, M230I/L

http://hivdb.stanford.edu Kulkarni R et al. JAIDS; 59(1): 47-54.





	Efavirenz	Nevirapine	Rilpivirine	Etravirine
E138K	10	10	30	10

*Key point: NNRTI cross-resistance is more common with rilpivine than efavirenz

Penalty score >60: high-level resistance 30-60: intermediate-level resistance 10-30: low-level resistance Less than 0: hypersusceptible



- A 45-year-old woman presents for an initial visit. She doesn't recall the names of the ARV's she was taking most recently and has been off of them for 4 weeks.
- You perform a genotype resistance assay and find the following NNRTI mutations: K103N, Y181I and P225H.
- Is etravirine an option for this patient?

```
NNRTI DRUGS

RESCRIPTOR, (delavirdine, DLV)

SUSTIVA, (efavirenz, EFV)

VIRAMUNE, (nevirapine, NVP)

INTELENCE, (etravirine, ETR)

NNRTI associated resistance mutations found: K103N,

Y181I, P225H
```

Etravirine Resistance

- Etravirine may retain activity even if resistance develops to other NNRTI's
- Depends on # of mutations and which specific mutations
- Most significant: Y181C/I/V
- Best way to determine susceptibility: phenotype
 - Methods to estimate susceptibility:
 - DUET (Tibotec) weighted scoring system
 - Monogram Biosciences weighted scoring system

Libre JM, Schapiro JM, Clotet B. CID. 2010;(50),872-881.



Etravirine: DUET Score

Weight	Mutations
3	Y181I/V
2.5	L100I, K101P, Y181C, M230L
1.5	V106I, E138A, V179F, G190S
1	V90I, A98G, K101E/H, V179D/T, G190A

*Response rates based on total score: 0-2: 74% (highest response) 2.5-3.5: 52% (intermediate response) >4.0: 38% (progressively reduced response)

Rathbun RC et al. Infections in Medicine. 2009;29(4).



Etravirine: Monogram "Enhanced" Score

Weight	Mutation
4	L100I, K101P, Y181C/I/V
3	E138A/G, V179E, G190Q, M230L, K238N
2	K101E, V106A/I, E138K, V179L, Y188L, G190S,
1	V90I, A98G, K101H, K103R, V106M, E138Q, V179D/F/I/M/T, Y181F, V189I, G190A/E/T, H221Y, P225H, K238T

Total score \geq 4 correlates with fold-change on phenotype that indicates resistance (90% sensitivity, 85% specificity)

Vingerhoets J et al. CROI 2010.



Summary of Key Mutations

- Efavirenz: K103N, also knocks out nevirapine
- Nevirapine: Y181C, more etravirine cross-resistance
- Rilpivirine: E138K +/- M184I, more NNRTI cross-resistance
- Etravirine: scoring systems estimate degree of resistance

